Marketing of Protein and Peptide Pharmaceuticals
•
1 like•826 views
The document discusses proteins and peptides as pharmaceutical drugs. It provides an overview of the protein therapeutics market, major brands that generate over $1 million in revenue, production costs, challenges of developing protein and peptide drugs, and regulatory considerations for approval of drugs derived from recombinant DNA technology.
Report
Share
Report
Share
![Proteins, eventually !! ,[object Object]](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)
Recommended
Biosimilars
This document discusses biosimilars, which are biologic medications that are similar but not identical to an original branded biologic. It notes that biosimilars are distinct from generic chemical drugs due to biological drugs' larger size and more complex structures. The document outlines regulatory approval pathways for biosimilars in Europe and the US, and summarizes concerns regarding biosimilars' safety, potential for automatic substitution, naming conventions, and labeling requirements compared to their reference products.
Biosimilars and generics
This document discusses biologics and biosimilars. It defines biologics as biological products made from natural sources like humans, animals or microorganisms that are used to treat or prevent diseases. Biosimilars are highly similar versions of biologics that are approved because they have no clinically meaningful differences. The document outlines key differences between biologics and biosimilars like regulatory pathways and development testing. It also compares biosimilars to generics and discusses important considerations for biosimilar development like immunogenicity, bioequivalence and post-translational modification.
Biosimilars in rheumatology
A brief description of biosimilars used in rheumatology, with particular reference to the Indian scenario.
9. Dr. Thomas Schreitmueller - F. Hoffmann-La Roche
9. Dr. Thomas Schreitmueller - F. Hoffmann-La RocheInternational Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
“The Evolution of Pharmaceutical Biotechnology – Science, Strategies, Products, and Regulations”
Shows the latest developments in pharmaceutical biotechnology and provides a broad overview of biotherapeutic & biosimilar regulations globally and in the EU Combating drug resistance in anticancer therapy
This document discusses strategies to combat drug resistance in anticancer therapy. It notes that continuous monitoring of patients and using a cocktail of drugs targeting multiple resistance pathways can help overcome resistance. Another strategy is intermittent "on and off" high and low dosing to interrupt growth of resistant cells. Blocking P-glycoprotein and depleting ATP can decrease drug resistance by inhibiting drug efflux. Using nanoparticles loaded with chemotherapy drugs and targeting molecules allows drugs to enter cancer cells. Genetic changes that increase drug-deactivating enzymes, membrane transporters, or DNA repair can also cause resistance.
Drug discoverydevelopment
Drug discovery and development involves several basic steps: choosing a disease target and drug target, identifying a lead compound, optimizing the lead compound's structure through structure-activity relationships, determining toxicity and efficacy in animal models, and carrying out clinical trials in humans. Key parts of the process include identifying the pharmacophore of active compounds, improving pharmacokinetic properties like absorption and metabolism, ensuring safety through toxicity testing, and developing an efficient manufacturing process. Thalidomide highlights the importance of thorough safety testing, as its approval without adequate pregnancy testing led to severe birth defects in thousands of children.
QPS Biosimilar Bioanalytical Approaches
This presentation contains recommendations and requirements for the design of bioanalytical testing used in comparibility studies for biosimilar drug development using rituximab as an example
FDA 2013 Clinical Investigator Training Course: Biosimilar Biological Products
This document provides an overview of biosimilar biological products from a presentation given by Dr. Sue Lim of the FDA. It defines biological products and biosimilars. Biosimilars are developed using a stepwise approach to demonstrate biosimilarity to a reference product through analytical, nonclinical and clinical studies. Clinical study design considerations for biosimilars include using endpoints sensitive to potential differences, assessing products at time points most likely to detect differences, using the same or similar patient populations and doses as the reference product, and evaluating safety including immunogenicity over a duration adequate to detect potential impacts.
Recommended
Biosimilars
This document discusses biosimilars, which are biologic medications that are similar but not identical to an original branded biologic. It notes that biosimilars are distinct from generic chemical drugs due to biological drugs' larger size and more complex structures. The document outlines regulatory approval pathways for biosimilars in Europe and the US, and summarizes concerns regarding biosimilars' safety, potential for automatic substitution, naming conventions, and labeling requirements compared to their reference products.
Biosimilars and generics
This document discusses biologics and biosimilars. It defines biologics as biological products made from natural sources like humans, animals or microorganisms that are used to treat or prevent diseases. Biosimilars are highly similar versions of biologics that are approved because they have no clinically meaningful differences. The document outlines key differences between biologics and biosimilars like regulatory pathways and development testing. It also compares biosimilars to generics and discusses important considerations for biosimilar development like immunogenicity, bioequivalence and post-translational modification.
Biosimilars in rheumatology
A brief description of biosimilars used in rheumatology, with particular reference to the Indian scenario.
9. Dr. Thomas Schreitmueller - F. Hoffmann-La Roche
9. Dr. Thomas Schreitmueller - F. Hoffmann-La RocheInternational Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
“The Evolution of Pharmaceutical Biotechnology – Science, Strategies, Products, and Regulations”
Shows the latest developments in pharmaceutical biotechnology and provides a broad overview of biotherapeutic & biosimilar regulations globally and in the EU Combating drug resistance in anticancer therapy
This document discusses strategies to combat drug resistance in anticancer therapy. It notes that continuous monitoring of patients and using a cocktail of drugs targeting multiple resistance pathways can help overcome resistance. Another strategy is intermittent "on and off" high and low dosing to interrupt growth of resistant cells. Blocking P-glycoprotein and depleting ATP can decrease drug resistance by inhibiting drug efflux. Using nanoparticles loaded with chemotherapy drugs and targeting molecules allows drugs to enter cancer cells. Genetic changes that increase drug-deactivating enzymes, membrane transporters, or DNA repair can also cause resistance.
Drug discoverydevelopment
Drug discovery and development involves several basic steps: choosing a disease target and drug target, identifying a lead compound, optimizing the lead compound's structure through structure-activity relationships, determining toxicity and efficacy in animal models, and carrying out clinical trials in humans. Key parts of the process include identifying the pharmacophore of active compounds, improving pharmacokinetic properties like absorption and metabolism, ensuring safety through toxicity testing, and developing an efficient manufacturing process. Thalidomide highlights the importance of thorough safety testing, as its approval without adequate pregnancy testing led to severe birth defects in thousands of children.
QPS Biosimilar Bioanalytical Approaches
This presentation contains recommendations and requirements for the design of bioanalytical testing used in comparibility studies for biosimilar drug development using rituximab as an example
FDA 2013 Clinical Investigator Training Course: Biosimilar Biological Products
This document provides an overview of biosimilar biological products from a presentation given by Dr. Sue Lim of the FDA. It defines biological products and biosimilars. Biosimilars are developed using a stepwise approach to demonstrate biosimilarity to a reference product through analytical, nonclinical and clinical studies. Clinical study design considerations for biosimilars include using endpoints sensitive to potential differences, assessing products at time points most likely to detect differences, using the same or similar patient populations and doses as the reference product, and evaluating safety including immunogenicity over a duration adequate to detect potential impacts.
concept of biosimilars
1) The document discusses the concept of biosimilars, including their definition as biological products that are similar but not identical to an approved biologic in terms of quality, safety and efficacy.
2) It provides an overview of the regulatory approval pathways for biosimilars in the European Union, United States, and India, which generally require demonstrating biosimilarity through comparative clinical and non-clinical studies.
3) The production of biologics is more complex than small molecule drugs due to biologics' larger size, more complex structures, instability, and potential microheterogeneity.
Biosimilars, biogenerics and fo bs
This document provides an executive summary of key information about biosimilars, biogenerics, and follow-on biologics. It discusses how biosimilars represent one of the most rapidly evolving areas in the pharmaceutical industry as patents on the first generation of biopharmaceuticals expire. The EU has legislation in place for biosimilar approval, while the US is working to pass similar legislation. The report profiles 15 companies involved in biosimilars development and forecasts that the global biosimilars market will grow from $30 million in 2006 to $3.2 billion in 2011, with Europe leading the way. It also summarizes the document's coverage of potential biosimilar targets, scientific and regulatory issues
Biosimilars: A biologic drug revolution
Definition of biopharmaceuticals and biosimilars, Steps involved in manufacturing biopharmaceuticals, Points of differences between Biosimilars and Chemical Generics, Related issues with biosimilars
12 Dr. Thomas Schreitmueller Roche
12 Dr. Thomas Schreitmueller RocheInternational Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
The document discusses the importance of selecting sensitive patient populations for clinical trials of biosimilar monoclonal antibodies to properly assess clinical similarity to the reference product. It provides examples of indications and populations that are more sensitive for detecting differences based on effect size, such as rheumatoid arthritis patients for assessing ACR20 response to anti-TNF antibodies. The document cautions that clinical trials must be designed appropriately to demonstrate equivalence or non-inferiority and should obtain data on relevant endpoints in sensitive populations as well as long-term safety and immunogenicity follow-up to justify extrapolation to other indications. It critiques examples of biosimilar clinical trials that failed to use a sensitive population or design.Pegylation & biosimilars global scenario
The document defines drugs and devices under the Drugs and Cosmetics Act of 1940 in India. It states that drugs include all medicines, substances and components for internal or external use, while devices are meant to treat, mitigate or prevent disease. Biologics and biosimilars are also included. The document then provides definitions and explanations of biotechnology, biopharmaceuticals, proteins drugs, pegylation, biologics vs biosimilars, and the FDA approach to biosimilars.
Drug Types: Biosimilars, generics and more. December 2017 Webinar 12122017
This document provides information about an upcoming webinar on drug types including biosimilars and generics. It outlines details like the speaker, how to ask questions during the webinar, and instructions for accessing the webinar archive and following along on Twitter. It also provides brief bios of the speaker and gives technical instructions for participating in the webinar platform. Finally, it lists some resources and includes a standard disclaimer.
Generics and Biogenerics
The document summarizes trends in research and development of generic drugs in the global pharmaceutical industry. It provides an overview of historical developments in generic drug maker PLIVA dating back to 1928, and its combination with Barr Group in 2006 to form a global generic pharmaceutical company. It also discusses trends in the generic drug market, strategies for differentiation, and key factors for success in generic drug research and development, emphasizing the importance of speed, intellectual property positioning, and internal API development capabilities.
Biosimilar - a mAb case study
Biosimilars are biological generics drugs.They undergo a rigorous evaluation to get approved.How to prove biosimilariy from analytical comparability is explained using a recently approved US FDA bio-similar monoclonal antibody.
Drug designing and discovery
Drug design involves modifying molecules to complement biological targets through computer modeling. The drug development process includes research, clinical trials, and addressing financial costs that can take 10-15 years and $897 million to $1.9 billion per drug. Key steps involve identifying drug targets, developing assays to test effectiveness, finding lead compounds through ligand- or structure-based design, and refining activity through pre-clinical and clinical trials for FDA approval. After approval, drugs are formulated, produced, marketed, and can be produced generically once patents expire.
Biosimilar
This document discusses biosimilar medicines. It defines biosimilars as medicines similar to existing approved biopharmaceutical medicines. Biosimilars have similar quality, safety and efficacy profiles but are not identical. Their development and approval process is more complex than for generics due to the biological nature of biopharmaceuticals which are sensitive to manufacturing changes. Guidelines from the European Medicines Agency provide recommendations on demonstrating biosimilarity in terms of quality, non-clinical and clinical testing. Ensuring biosimilars are highly similar seeks to guarantee their safe substitution for biopharmaceuticals while increasing treatment access and lowering costs.
Biological agents and it role in current era and future role
This document discusses biological agents and their role in medicine. It defines biological products and biosimilars, and describes how biosimilars differ from original biologics in their manufacturing process and ability to be replicated exactly. The document outlines regulatory guidelines for biosimilars from agencies like EMA and FDA. Biosimilars can expand access to biologic treatments for diseases like rheumatoid arthritis and have potential cost savings compared to originator biologics. Safety monitoring is important due to concerns like immunogenicity.
new biological targets by prathyusha .m
This document discusses new biological targets for drug development. It begins by defining biological targets and describing common targets such as G protein-coupled receptors, enzymes, and ligand-gated ion channels. Specific examples of new targets discussed include macrophages for HIV drugs, proteins involved in insulin signaling for diabetes therapies, and the cytokine IL-23 for inflammatory bowel disease. The document also mentions research into new targets for skin cancer, cardiovascular disease, and general efforts to identify novel drug targets from biological systems.
Therapuetic agents
This document discusses therapeutic agents derived from non-recombinant organisms. It notes that nature provides a diverse source of potential therapeutic agents from plants, animals, marine organisms and microbes. Specifically, it outlines that microbes have potential to produce drugs for diseases like cancer, anemia, and diabetes. The document then categorizes different types of therapeutic agents including enzymes, antimicrobial peptides, proteins, interferons and immunosuppressors. It provides examples of enzyme therapeutic uses such as oncolytics, anticoagulants, thrombolytics and metabolic deficiency replacements. The document concludes that organisms can be used to treat diseases like cancer, infections, and genetic disorders and that delivery strategies of therapeutic agents can be improved.
Biosimilars
- Biosimilars are biologic medical products that are similar but not identical copies of original biologic drugs. They are developed when the patent expires on the original product.
- Regulatory agencies have stringent approval criteria for biosimilars to demonstrate similar quality, safety and efficacy as the reference product. Clinical trials must show comparable pharmacokinetics, pharmacodynamics and immunogenicity.
- While biosimilars increase access and lower costs, they are not generic copies and have unique safety profiles. Automatic substitution is not appropriate and unique nonproprietary names and labeling is required to facilitate pharmacovigilance.
Theoretical basis and optimization of immunoassay
This document discusses the theoretical basis and optimization of immunoassays. It begins by introducing immunoassays and their importance in pharmaceutical analysis due to their specificity and sensitivity. It then describes the basic principles of immunoassays, including the competitive binding reaction between labeled and unlabeled analyte for antibody binding sites. The document categorizes different types of immunoassays and provides examples of their use. It also discusses optimization of immunoassays through techniques like minimizing background signals, improving precision and reproducibility, stabilizing conjugates, and increasing shelf-life. A key immunoassay method discussed is ELISA.
Chiral resolution by Vamsi Anil Krishna Chandu
This document discusses chiral drug technology and its importance in the pharmaceutical industry. It begins by introducing resolution methods like chromatography and kinetic resolution used to separate chiral compounds. It then discusses resolving agents and how they demonstrate stereoselectivity. Examples are given of major drug products that were originally racemates but are now only marketed as single enantiomers. Chiral drug sales have grown significantly in therapeutic areas like cardiovascular and cancer. The document concludes by stating that chiral technology represents a large commercial opportunity and that consideration of chirality is important in drug research and development due to regulatory guidelines.
Immunoassay of digoxin
1) Digoxin immunoassay is used to monitor digoxin levels in patients' serum since digoxin has a narrow therapeutic range and toxic levels can mimic disease symptoms.
2) Various analytical methods are used for digoxin immunoassay including radioimmunoassay, enzyme immunoassay, cloned enzyme donor immunoassay, fluorescence polarization immunoassay, and enzyme multiplied immunoassay.
3) The general procedure involves adding patient serum, labeled digoxin tracer, and antibody to wells before incubating and measuring enzyme activity, with the activity inversely proportional to digoxin concentration in the patient's serum sample.
Biosimilars
Increasing knowledge of genetics and cell processes leads to potential new biologic (and drug) targets at each step in the protein-production process. This leads to new therapies, which in turn lead to new understanding of diseases. Here is an update on relatively new drugs called biologics...
Us biosimilar guidance jim wei-june 2012 (3)
The document summarizes the key points of the FDA's 2012 guidance on biosimilars. It outlines the Biologics Price Competition and Innovation Act which created an approval pathway for biosimilar biological products. It describes the FDA's definitions and expectations for demonstrating biosimilarity through analytical, preclinical, and clinical studies comparing a proposed biosimilar to a reference product in a stepwise approach considering totality of evidence. The guidance addresses quality, scientific, and clinical considerations for biosimilar development and approval.
Biosimilars
Basic Information of Biosimilars. This ppt is basd on secondary data by various internet sites.
For downloading, send me an e-mail.
Protein and peptide d d s
This document discusses protein and peptide drug delivery systems. It begins by defining proteins and peptides, and describing their structures. It then discusses various challenges in delivering protein and peptide drugs, such as stability issues like denaturation, aggregation, oxidation, and proteolysis. It also categorizes different drug delivery routes like parenteral, pulmonary, transdermal, and oral. Finally, it provides examples of marketed protein and peptide drug formulations and discusses strategies to improve stability and delivery of these drugs.
protein and peptide drug delivery system
This document discusses protein and peptide drug delivery systems. It begins by defining proteins and peptides, and their importance in biological functions and pharmaceuticals. It then covers the classification and structures of proteins. Various routes of administration for protein and peptide drugs are examined, including parenteral routes like intravenous, intramuscular, and subcutaneous. Specific drug delivery systems like polymer-based, liposome-based, and hydrogel-based systems are outlined. Both implantable and mechanical pumps are mentioned for prolonged parenteral delivery. Non-parenteral routes such as oral, nasal, pulmonary and transdermal are also reviewed.
More Related Content
What's hot
concept of biosimilars
1) The document discusses the concept of biosimilars, including their definition as biological products that are similar but not identical to an approved biologic in terms of quality, safety and efficacy.
2) It provides an overview of the regulatory approval pathways for biosimilars in the European Union, United States, and India, which generally require demonstrating biosimilarity through comparative clinical and non-clinical studies.
3) The production of biologics is more complex than small molecule drugs due to biologics' larger size, more complex structures, instability, and potential microheterogeneity.
Biosimilars, biogenerics and fo bs
This document provides an executive summary of key information about biosimilars, biogenerics, and follow-on biologics. It discusses how biosimilars represent one of the most rapidly evolving areas in the pharmaceutical industry as patents on the first generation of biopharmaceuticals expire. The EU has legislation in place for biosimilar approval, while the US is working to pass similar legislation. The report profiles 15 companies involved in biosimilars development and forecasts that the global biosimilars market will grow from $30 million in 2006 to $3.2 billion in 2011, with Europe leading the way. It also summarizes the document's coverage of potential biosimilar targets, scientific and regulatory issues
Biosimilars: A biologic drug revolution
Definition of biopharmaceuticals and biosimilars, Steps involved in manufacturing biopharmaceuticals, Points of differences between Biosimilars and Chemical Generics, Related issues with biosimilars
12 Dr. Thomas Schreitmueller Roche
12 Dr. Thomas Schreitmueller RocheInternational Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
The document discusses the importance of selecting sensitive patient populations for clinical trials of biosimilar monoclonal antibodies to properly assess clinical similarity to the reference product. It provides examples of indications and populations that are more sensitive for detecting differences based on effect size, such as rheumatoid arthritis patients for assessing ACR20 response to anti-TNF antibodies. The document cautions that clinical trials must be designed appropriately to demonstrate equivalence or non-inferiority and should obtain data on relevant endpoints in sensitive populations as well as long-term safety and immunogenicity follow-up to justify extrapolation to other indications. It critiques examples of biosimilar clinical trials that failed to use a sensitive population or design.Pegylation & biosimilars global scenario
The document defines drugs and devices under the Drugs and Cosmetics Act of 1940 in India. It states that drugs include all medicines, substances and components for internal or external use, while devices are meant to treat, mitigate or prevent disease. Biologics and biosimilars are also included. The document then provides definitions and explanations of biotechnology, biopharmaceuticals, proteins drugs, pegylation, biologics vs biosimilars, and the FDA approach to biosimilars.
Drug Types: Biosimilars, generics and more. December 2017 Webinar 12122017
This document provides information about an upcoming webinar on drug types including biosimilars and generics. It outlines details like the speaker, how to ask questions during the webinar, and instructions for accessing the webinar archive and following along on Twitter. It also provides brief bios of the speaker and gives technical instructions for participating in the webinar platform. Finally, it lists some resources and includes a standard disclaimer.
Generics and Biogenerics
The document summarizes trends in research and development of generic drugs in the global pharmaceutical industry. It provides an overview of historical developments in generic drug maker PLIVA dating back to 1928, and its combination with Barr Group in 2006 to form a global generic pharmaceutical company. It also discusses trends in the generic drug market, strategies for differentiation, and key factors for success in generic drug research and development, emphasizing the importance of speed, intellectual property positioning, and internal API development capabilities.
Biosimilar - a mAb case study
Biosimilars are biological generics drugs.They undergo a rigorous evaluation to get approved.How to prove biosimilariy from analytical comparability is explained using a recently approved US FDA bio-similar monoclonal antibody.
Drug designing and discovery
Drug design involves modifying molecules to complement biological targets through computer modeling. The drug development process includes research, clinical trials, and addressing financial costs that can take 10-15 years and $897 million to $1.9 billion per drug. Key steps involve identifying drug targets, developing assays to test effectiveness, finding lead compounds through ligand- or structure-based design, and refining activity through pre-clinical and clinical trials for FDA approval. After approval, drugs are formulated, produced, marketed, and can be produced generically once patents expire.
Biosimilar
This document discusses biosimilar medicines. It defines biosimilars as medicines similar to existing approved biopharmaceutical medicines. Biosimilars have similar quality, safety and efficacy profiles but are not identical. Their development and approval process is more complex than for generics due to the biological nature of biopharmaceuticals which are sensitive to manufacturing changes. Guidelines from the European Medicines Agency provide recommendations on demonstrating biosimilarity in terms of quality, non-clinical and clinical testing. Ensuring biosimilars are highly similar seeks to guarantee their safe substitution for biopharmaceuticals while increasing treatment access and lowering costs.
Biological agents and it role in current era and future role
This document discusses biological agents and their role in medicine. It defines biological products and biosimilars, and describes how biosimilars differ from original biologics in their manufacturing process and ability to be replicated exactly. The document outlines regulatory guidelines for biosimilars from agencies like EMA and FDA. Biosimilars can expand access to biologic treatments for diseases like rheumatoid arthritis and have potential cost savings compared to originator biologics. Safety monitoring is important due to concerns like immunogenicity.
new biological targets by prathyusha .m
This document discusses new biological targets for drug development. It begins by defining biological targets and describing common targets such as G protein-coupled receptors, enzymes, and ligand-gated ion channels. Specific examples of new targets discussed include macrophages for HIV drugs, proteins involved in insulin signaling for diabetes therapies, and the cytokine IL-23 for inflammatory bowel disease. The document also mentions research into new targets for skin cancer, cardiovascular disease, and general efforts to identify novel drug targets from biological systems.
Therapuetic agents
This document discusses therapeutic agents derived from non-recombinant organisms. It notes that nature provides a diverse source of potential therapeutic agents from plants, animals, marine organisms and microbes. Specifically, it outlines that microbes have potential to produce drugs for diseases like cancer, anemia, and diabetes. The document then categorizes different types of therapeutic agents including enzymes, antimicrobial peptides, proteins, interferons and immunosuppressors. It provides examples of enzyme therapeutic uses such as oncolytics, anticoagulants, thrombolytics and metabolic deficiency replacements. The document concludes that organisms can be used to treat diseases like cancer, infections, and genetic disorders and that delivery strategies of therapeutic agents can be improved.
Biosimilars
- Biosimilars are biologic medical products that are similar but not identical copies of original biologic drugs. They are developed when the patent expires on the original product.
- Regulatory agencies have stringent approval criteria for biosimilars to demonstrate similar quality, safety and efficacy as the reference product. Clinical trials must show comparable pharmacokinetics, pharmacodynamics and immunogenicity.
- While biosimilars increase access and lower costs, they are not generic copies and have unique safety profiles. Automatic substitution is not appropriate and unique nonproprietary names and labeling is required to facilitate pharmacovigilance.
Theoretical basis and optimization of immunoassay
This document discusses the theoretical basis and optimization of immunoassays. It begins by introducing immunoassays and their importance in pharmaceutical analysis due to their specificity and sensitivity. It then describes the basic principles of immunoassays, including the competitive binding reaction between labeled and unlabeled analyte for antibody binding sites. The document categorizes different types of immunoassays and provides examples of their use. It also discusses optimization of immunoassays through techniques like minimizing background signals, improving precision and reproducibility, stabilizing conjugates, and increasing shelf-life. A key immunoassay method discussed is ELISA.
Chiral resolution by Vamsi Anil Krishna Chandu
This document discusses chiral drug technology and its importance in the pharmaceutical industry. It begins by introducing resolution methods like chromatography and kinetic resolution used to separate chiral compounds. It then discusses resolving agents and how they demonstrate stereoselectivity. Examples are given of major drug products that were originally racemates but are now only marketed as single enantiomers. Chiral drug sales have grown significantly in therapeutic areas like cardiovascular and cancer. The document concludes by stating that chiral technology represents a large commercial opportunity and that consideration of chirality is important in drug research and development due to regulatory guidelines.
Immunoassay of digoxin
1) Digoxin immunoassay is used to monitor digoxin levels in patients' serum since digoxin has a narrow therapeutic range and toxic levels can mimic disease symptoms.
2) Various analytical methods are used for digoxin immunoassay including radioimmunoassay, enzyme immunoassay, cloned enzyme donor immunoassay, fluorescence polarization immunoassay, and enzyme multiplied immunoassay.
3) The general procedure involves adding patient serum, labeled digoxin tracer, and antibody to wells before incubating and measuring enzyme activity, with the activity inversely proportional to digoxin concentration in the patient's serum sample.
Biosimilars
Increasing knowledge of genetics and cell processes leads to potential new biologic (and drug) targets at each step in the protein-production process. This leads to new therapies, which in turn lead to new understanding of diseases. Here is an update on relatively new drugs called biologics...
Us biosimilar guidance jim wei-june 2012 (3)
The document summarizes the key points of the FDA's 2012 guidance on biosimilars. It outlines the Biologics Price Competition and Innovation Act which created an approval pathway for biosimilar biological products. It describes the FDA's definitions and expectations for demonstrating biosimilarity through analytical, preclinical, and clinical studies comparing a proposed biosimilar to a reference product in a stepwise approach considering totality of evidence. The guidance addresses quality, scientific, and clinical considerations for biosimilar development and approval.
Biosimilars
Basic Information of Biosimilars. This ppt is basd on secondary data by various internet sites.
For downloading, send me an e-mail.
What's hot (20)
Drug Types: Biosimilars, generics and more. December 2017 Webinar 12122017
Drug Types: Biosimilars, generics and more. December 2017 Webinar 12122017
Biological agents and it role in current era and future role
Biological agents and it role in current era and future role
Viewers also liked
Protein and peptide d d s
This document discusses protein and peptide drug delivery systems. It begins by defining proteins and peptides, and describing their structures. It then discusses various challenges in delivering protein and peptide drugs, such as stability issues like denaturation, aggregation, oxidation, and proteolysis. It also categorizes different drug delivery routes like parenteral, pulmonary, transdermal, and oral. Finally, it provides examples of marketed protein and peptide drug formulations and discusses strategies to improve stability and delivery of these drugs.
protein and peptide drug delivery system
This document discusses protein and peptide drug delivery systems. It begins by defining proteins and peptides, and their importance in biological functions and pharmaceuticals. It then covers the classification and structures of proteins. Various routes of administration for protein and peptide drugs are examined, including parenteral routes like intravenous, intramuscular, and subcutaneous. Specific drug delivery systems like polymer-based, liposome-based, and hydrogel-based systems are outlined. Both implantable and mechanical pumps are mentioned for prolonged parenteral delivery. Non-parenteral routes such as oral, nasal, pulmonary and transdermal are also reviewed.
Signature Peptide MRM Optimization Made Easy for Therapeutic Protein and Pept...
This technical note describes the results of experiments where DiscoveryQuantTM software was used to optimize compound dependent parameters and improve upon the sensitivity oAf methods obtained from the output of Skyline software for the quantitation of peptides.
Protein and peptide drug delivery system (PPDDS)
Protein and Peptide drug delivery system are the Novel drug Delivery
System. Proteins and peptides are the most abundant components of
biological cells. They exist functioning such as enzymes, hormones, structural element and immunoglobulin.
Leptin
This PowerPoint presentation shares vital information on leptin and exactly what comprises the foundation for the Venus Factor system. Leptin is a powerful enzyme for weight loss and because of this, proper leptin resistance management has provided great success to women wanting to burn fat.
Protein drug delivery systems2
This document discusses proteins and peptides as drug delivery systems. It covers the structure and classification of proteins, as well as stability problems such as denaturation, aggregation, oxidation, and proteolysis. Common excipients used to address these issues are presented. Several marketed protein and peptide drugs are listed along with their formulations and medical applications. The conclusion emphasizes that protein and peptide drugs will replace many existing pharmaceuticals, posing a challenge to develop viable delivery systems for non-parenteral administration.
Pharmacotherpy & Recent Advances in Obesity Management
This document provides an overview of pharmacotherapy and recent advances in obesity management. It discusses the definition and classification of overweight and obesity, the physiology of feeding and energy expenditure, and various drug classes used for obesity treatment including orlistat, lorcaserin, bupropion, and others. It summarizes key clinical trials demonstrating the efficacy and safety of these drugs, alone or in combination with lifestyle modifications, for achieving clinically meaningful weight loss.
Protein
Protein and peptide drugs can be delivered through various routes including parenteral, oral, buccal, nasal, transdermal, pulmonary, rectal, ocular, and vaginal administration. Various drug delivery systems are used to protect proteins from degradation and control release over time. These include microencapsulation, polymeric scaffolds, liposomes, magnetic targeting, and hydrogels. Recent advances provide more effective noninvasive delivery methods for these therapeutic compounds.
Leptin ppt
This document discusses leptin, a hormone that regulates body weight. It describes how leptin is produced in fat cells and acts in the hypothalamus to reduce appetite. Leptin resistance, where the body becomes insensitive to leptin, is a major factor in obesity. The document also outlines the physiological effects of leptin, factors that influence its expression, and potential leptin-targeting drugs for treating obesity and related conditions.
Protein and peptide drug delivery seminar-97-2003-final2
The document discusses protein and peptide drug delivery. It covers the introduction to proteins and peptides, routes of absorption, properties that present challenges for delivery, and various pharmaceutical approaches to overcome these challenges. These approaches include chemical modification through prodrug approaches, use of enzyme inhibitors, penetration enhancers, and formulation vehicles like dry emulsions, microspheres, liposomes and nanoparticles. It also discusses stability aspects and recent advances in delivery of therapeutic proteins and peptides.
Protein and-peptide-drug-delivery-systems
The document discusses protein and peptide drug delivery systems. It begins by defining proteins and peptides, noting that proteins are molecules composed of over 50 amino acids, while peptides are molecules composed of less than 50 amino acids. It then discusses how scientific advances in molecular and cell biology have led to the development of recombinant DNA and hybridoma technology to produce protein products. The document provides examples of marketed protein and peptide drugs and discusses challenges with delivering these drugs orally due to their large molecular size and susceptibility to enzymatic degradation. It explores approaches to protein and peptide delivery including non-parenteral systemic delivery methods and various considerations for developing delivery systems for these pharmaceuticals.
Protein and peptide drug delivery system
Protein and Peptide drug delivery system are the Novel drug Delivery System. Proteins and peptides are the most abundant components of biological cells. They exist functioning such as
enzymes, hormones, structural element and immunoglobulin. The distinction between peptides and proteins is having a peptide contains less than 20 amino acids, having a molecular weight less, while a protein possesses 50 or more amino acids and its molecular weight lies above this value. The most of pharmaceutical proteins and peptides are absorbed IM, IV and Subcutaneous route of Absorption, but the oral route is more convenient for absorption of protein as compared to other. Various problems associated with administration of protein and peptide drugs are needed to overcome by different pharmaceutical approaches. Several approaches available for
maximizing pharmacokinetic and pharmacodynamics properties are chemical modification,
formulation vehicles, mucoadhesive polymeric system, use of enzyme inhibitors, absorption
enhancers, penetration enhancers etc.
Protein and peptide delivery system
This slide show is created for the purpose of helping pharma people involved in research in drug delivery methods.
Peptides
Peptides are short chains of amino acids linked by peptide bonds. They are distinguished from proteins by typically containing fewer than 50 amino acid units. Peptides are formed through condensation reactions between carboxyl and amino groups of separate amino acids, releasing a water molecule. Peptide bonds are rigid and planar, contributing to protein structure stability. Peptides serve many important biological functions and can be classified based on their production method, including through ribosomal translation, nonribosomal synthesis, and enzymatic digestion of proteins in foods. Bioactive peptides derived from food proteins can have beneficial effects like lowering blood pressure, cholesterol, and antimicrobial properties.
Stratégies de récupération en trail & ultra-trail [YLM 2015]
Stratégies de récupération en trail & ultra-trail [YLM 2015]
Commercialisation des aliments en 2009
Démystifiez la structure du marché du commerce du détail, identifiez les impairs à ne pas commettre et identifiez des stratégies pour à réussir leurs initiatives de commercialisation.
S'adresse autant aux petites qu'aux moyennes entreprises en agroalimentaire
Etude de Cas Marketing Levi's
Analyse marketing de Levi's et plus particulièrement sur le 501. Réalisation pour le cours de Marketing à l'Efrei.
Marketing - Etude de cas : NESPRESSO
Étude du cas NEPRESSO, réalisée dans le cadre d'un cours d'introduction au marketing. Mise en page et publiée par Elise Fauvel.
Viewers also liked (20)
Signature Peptide MRM Optimization Made Easy for Therapeutic Protein and Pept...
Signature Peptide MRM Optimization Made Easy for Therapeutic Protein and Pept...
Pharmacotherpy & Recent Advances in Obesity Management
Pharmacotherpy & Recent Advances in Obesity Management
Protein and peptide drug delivery seminar-97-2003-final2
Protein and peptide drug delivery seminar-97-2003-final2
Stratégies de récupération en trail & ultra-trail [YLM 2015]
Stratégies de récupération en trail & ultra-trail [YLM 2015]
Similar to Marketing of Protein and Peptide Pharmaceuticals
Future trends and perspectives in modern pharmaceutical biotechnology
1. The document discusses trends and perspectives in modern pharmaceutical biotechnology, including the development from traditional biotechnology using secondary metabolites to modern biotechnology using recombinant DNA techniques.
2. It describes the transition from first generation biopharmaceuticals that mimic natural proteins to second generation biopharmaceuticals with improved properties through techniques like PEGylation, protein engineering, and protein fusions.
3. The introduction of biosimilars, advances in gene therapy and tissue engineering, and progress toward personalized drug therapy are also discussed as important trends and future perspectives in the field.
20091109 Biol1010 Personalized Medicine
Personalized medicine involves the prescription of specific therapeutics best suited for an individual based on their genetic or proteomic profile. This talk discusses current approaches in drug discovery/development, the role of genetics in drug metabolism, and lawful/ethical issues surrounding the deployment of new health technology. I highlight some bioinformatic roles in the drug discovery process, and discuss the use of semantic web technologies for data integration and knowledge discovery..
Genomic proteomics
The drug development process involves several key steps:
1. Discovery and initial characterization of a drug candidate through preclinical trials in animals.
2. Submission of preclinical data to regulatory authorities for approval of clinical trials in humans, which involve 3 phases over 5+ years.
3. Submission of clinical trial data and manufacturing information for regulatory review and approval.
4. If approved, the new drug is available on the market and undergoes post-marketing surveillance for side effects.
biosimilar-intended copies--mohie.pdf
This document discusses biosimilars and intended copies of biological drugs. It defines biosimilars as biological products that are highly similar to an original biologic and are approved through a rigorous regulatory process requiring demonstration of similarity. Intended copies are defined as biological products that claim similarity but did not undergo the same rigorous approval process. The document outlines key differences between biosimilars and intended copies, including higher heterogeneity and lack of established comparability for intended copies. It analyzes several intended copy products for etanercept and concludes they do not meet criteria for demonstrating comparability to the original product. The document emphasizes the importance of well-designed comparative clinical studies for determining similarity of intended copies to original biologics.
biosimilar-intended copies--mohie.pdf
The document discusses the key differences between intended copies, biosimilars, and original biological products. Intended copies are biological products that show similarity to originals but did not undergo rigorous regulatory approval per WHO/EMA/FDA guidelines. Biosimilars demonstrate similarity to originals based on comprehensive analytical, nonclinical, and clinical studies. In contrast to biosimilars, intended copies have shown more heterogeneity, lack established comparability, and have limited clinical data published. The document concludes intended copies should not be considered interchangeable with original products due to lack of sufficient data on their efficacy and safety.
Peptides assignment , m.alyami
This document discusses the therapeutic applications of peptides. It begins by providing background on peptides, their structures, and natural sources. It then discusses several therapeutic uses of peptides including as anticancer agents, hormones for treating conditions like prostate cancer, carriers for delivering cytotoxic drugs to cancer cells, treatments for diabetes, anti-obesity, and pre-term labor. The document also discusses peptide manufacturing methods, diagnostic uses of peptides, and antimicrobial peptides.
pharmacogenomicspptnsu-191212202112 (1).pptx
Pharmacogenomics aims to optimize drug therapy based on a patient's genotype. Genetic factors can account for 20-95% of variability in drug response. Polymorphisms like SNPs that occur in over 1% of a population can impact drug metabolism and effects. Pharmacogenomic testing targets biomarkers for specific drug classes to determine efficacy and avoid toxicity. While it has potential to improve prescribing, limitations include many genes influencing drugs and ethical issues. Personalized medicine based on pharmacogenomics is still developing.
Biosimilars: assets and sustainability, between regulation and information
The document discusses biosimilars and biopharmaceuticals. It defines biopharmaceuticals as pharmaceuticals produced through biotechnology methods, including recombinant DNA technology and products extracted from biological sources. Biosimilars are similar but not identical copies of biopharmaceuticals whose patents have expired. Unlike generics, biosimilars cannot be proven bioequivalent due to inherent variability in biological manufacturing processes. Biosimilars undergo a rigorous approval process involving comparability exercises to demonstrate similarity in quality, safety and efficacy to the reference product.
Towards Personalized Medicine
Personalized medicine involves the prescription of specific therapeutics best suited for an individual based on their genetic or proteomic profile. This talk discusses current approaches in drug discovery/development, the role of genetics in drug metabolism, and lawful/ethical issues surrounding the deployment of new health technology.
31. Immunogenicity of Biologicals: Clinical Consequences
31. Immunogenicity of Biologicals: Clinical ConsequencesInternational Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
This document summarizes key information about biological drugs and biosimilars, including:
1) It defines biologicals as drugs derived from biological sources using biotechnology like recombinant DNA or monoclonal antibody techniques. Biologicals have higher molecular weights and more complex structures than traditional drugs.
2) Immunogenicity, or the potential to provoke an immune response, is a major difference between biologicals and traditional drugs and can reduce efficacy of biologicals.
3) Several studies found biosimilars of biological drugs like alpha interferon and alpha erythropoietin showed differences in quality, efficacy, and safety compared to reference products in some cases.
4) Antibodies developed against biologicals canPotential role of bioactive peptides in prevention and treatment of chronic d...
This review analyzes studies and clinical trials on bioactive peptides and their potential roles in preventing and treating chronic diseases. The review focuses on cardiovascular diseases, immunity, cancer, and other areas. Bioactive peptides from various food sources like fish, milk, meat, and plants have shown effects like lowering blood pressure and lipids in clinical trials. Some peptides also demonstrate anticancer activity in vitro and in vivo as well as immunomodulatory and antimicrobial effects. However, more clinical evidence and standardized extraction procedures are still needed to confirm these effects and enable use of bioactive peptides as preventive or therapeutic treatments.
Drug discovery
an introduction to drug discovery process
involves need for drug dicovery,various pathways of drug development,steps in drug discovery
drug discovery- history, evolution and stages
introduction to drug discovery,history of drug development , drug development pathways, steps in drug discovery
Introduction to practical pharmacology
introduction to practical pharmacology, various experimental animal uses, CPCSEA guidelines, different phases of clinical trial, pre-clinical trial, important pharmacological definition
Opensourcepharma Dr Nibedita rath
Access to Research
Date 11-08-2018
Venue Conference HAll NIAS IISc campus
Conference and workshops for clinical practitioners to introduce them to modern tools and an alternative approach to modern scientific research.
Purpose
1. Build a network of physicians across the country
2 Train physicians to analyse clinical data and restructure it to make it compatible with research standards
3. Introduce modern tools to understand the mechanism of actions of medicine
4. Introduce artificial intelligence and machine learning to clinical practitioners to support decision-making processes
Access to Science
Clinical experience and traditional knowledge are important sources of data that affect decision making processes in modern healthcare systems. This data should be made accessible for scientific evaluation and validation to improve healthcare worldwide. The Open Source Pharma Foundation believes that clinical practitioners from various disciplines should have the right to access research so that they can help identify problems, contribute their scientific knowledge, and support the discovery ecosystem.
Background
The majority of medical practitioners working on the ground level with patients do not take part in open clinical research worldwide. However, the data collected and owned by them plays an important role in establishing better discovery pathways. Through this workshop, we seek to open opportunities to enhance health care systems around the world and to overcome the following challenges faced by medical practitioners.
1. Regulatory limitations
2. Academic limitations
3. Time constraints
4. Lack of access to modern tools
Pharmacogenomics- a step to personalized medicines
Pharmacogenomics aims to optimize drug therapy based on a patient's genotype to maximize efficacy and minimize adverse effects. It involves studying how genetic factors influence individual responses to drugs in terms of absorption, distribution, metabolism, and excretion. Genetic polymorphisms like SNPs that occur in over 1% of the population can impact a drug's effects. Pharmacogenomic testing identifies biomarkers related to drug metabolism and targets to determine effective treatments and dosages for patients. While it holds promise for improving drug development and personalized medicine, limitations include insufficient validation and high costs.
07 June (Day 6) PBRS 2015 PMS & DS
The document discusses post-marketing drug safety and surveillance. It begins by discussing the thalidomide tragedy in the 1950s and 1960s that led to increased regulation. It then discusses several more recent drug safety issues in the 21st century. The bulk of the document focuses on the importance of pharmacovigilance and post-marketing surveillance in monitoring drug safety, identifying new risks, and ensuring drug quality after approval. It describes the goals, principles, and methods of post-marketing surveillance and emphasizes its critical role in balancing drug efficacy and safety.
Homspera march2010
The document discusses a biotechnology company focused on developing products that regenerate or strengthen the human immune system. It summarizes results showing that the company's drug candidate Homspera stimulates hematopoietic stem cells, increasing white blood cell and platelet production. Studies also suggest Homspera may help resolve neutropenia caused by radiation exposure and chemotherapy by boosting white blood cell counts in irradiated animals.
Drug development process
Pre-discovery
Understand the disease
Target Identification
Choose a molecule to target with a drug
Target Validation
Test the target and confirm its role in the disease
Drug Discovery
Find a promising molecule (a “lead compound”)
that could become a drug
Biologicals and biosimilars a review of the science and its implications
Biologicals and biosimilars a review of the science and its implicationsNational Institute of Biologics
Biologicals and biosimilars are complex drugs produced by living cells. Biosimilars are similar but not identical copies of biological reference drugs. Regulatory requirements for biosimilars are more extensive than generics but less so than original biological drugs. Biosimilars require comparative quality analysis, limited clinical trials and toxicity studies against the reference drug. Due to inherent structural differences, biosimilars cannot be considered interchangeable with the reference drug.Similar to Marketing of Protein and Peptide Pharmaceuticals (20)
Future trends and perspectives in modern pharmaceutical biotechnology
Future trends and perspectives in modern pharmaceutical biotechnology
Biosimilars: assets and sustainability, between regulation and information
Biosimilars: assets and sustainability, between regulation and information
31. Immunogenicity of Biologicals: Clinical Consequences
31. Immunogenicity of Biologicals: Clinical Consequences
Potential role of bioactive peptides in prevention and treatment of chronic d...
Potential role of bioactive peptides in prevention and treatment of chronic d...
Pharmacogenomics- a step to personalized medicines
Pharmacogenomics- a step to personalized medicines
Biologicals and biosimilars a review of the science and its implications
Biologicals and biosimilars a review of the science and its implications
Recently uploaded
Skybuffer AI: Advanced Conversational and Generative AI Solution on SAP Busin...
Skybuffer AI, built on the robust SAP Business Technology Platform (SAP BTP), is the latest and most advanced version of our AI development, reaffirming our commitment to delivering top-tier AI solutions. Skybuffer AI harnesses all the innovative capabilities of the SAP BTP in the AI domain, from Conversational AI to cutting-edge Generative AI and Retrieval-Augmented Generation (RAG). It also helps SAP customers safeguard their investments into SAP Conversational AI and ensure a seamless, one-click transition to SAP Business AI.
With Skybuffer AI, various AI models can be integrated into a single communication channel such as Microsoft Teams. This integration empowers business users with insights drawn from SAP backend systems, enterprise documents, and the expansive knowledge of Generative AI. And the best part of it is that it is all managed through our intuitive no-code Action Server interface, requiring no extensive coding knowledge and making the advanced AI accessible to more users.
TrustArc Webinar - 2024 Global Privacy Survey
How does your privacy program stack up against your peers? What challenges are privacy teams tackling and prioritizing in 2024?
In the fifth annual Global Privacy Benchmarks Survey, we asked over 1,800 global privacy professionals and business executives to share their perspectives on the current state of privacy inside and outside of their organizations. This year’s report focused on emerging areas of importance for privacy and compliance professionals, including considerations and implications of Artificial Intelligence (AI) technologies, building brand trust, and different approaches for achieving higher privacy competence scores.
See how organizational priorities and strategic approaches to data security and privacy are evolving around the globe.
This webinar will review:
- The top 10 privacy insights from the fifth annual Global Privacy Benchmarks Survey
- The top challenges for privacy leaders, practitioners, and organizations in 2024
- Key themes to consider in developing and maintaining your privacy program
dbms calicut university B. sc Cs 4th sem.pdf
Its a seminar ppt on database management system using sql
AWS Cloud Cost Optimization Presentation.pptx
This presentation provides valuable insights into effective cost-saving techniques on AWS. Learn how to optimize your AWS resources by rightsizing, increasing elasticity, picking the right storage class, and choosing the best pricing model. Additionally, discover essential governance mechanisms to ensure continuous cost efficiency. Whether you are new to AWS or an experienced user, this presentation provides clear and practical tips to help you reduce your cloud costs and get the most out of your budget.
Presentation of the OECD Artificial Intelligence Review of Germany
Consult the full report at https://www.oecd.org/digital/oecd-artificial-intelligence-review-of-germany-609808d6-en.htm
Best 20 SEO Techniques To Improve Website Visibility In SERP
Boost your website's visibility with proven SEO techniques! Our latest blog dives into essential strategies to enhance your online presence, increase traffic, and rank higher on search engines. From keyword optimization to quality content creation, learn how to make your site stand out in the crowded digital landscape. Discover actionable tips and expert insights to elevate your SEO game.
Operating System Used by Users in day-to-day life.pptx
Dive into the realm of operating systems (OS) with Pravash Chandra Das, a seasoned Digital Forensic Analyst, as your guide. 🚀 This comprehensive presentation illuminates the core concepts, types, and evolution of OS, essential for understanding modern computing landscapes.
Beginning with the foundational definition, Das clarifies the pivotal role of OS as system software orchestrating hardware resources, software applications, and user interactions. Through succinct descriptions, he delineates the diverse types of OS, from single-user, single-task environments like early MS-DOS iterations, to multi-user, multi-tasking systems exemplified by modern Linux distributions.
Crucial components like the kernel and shell are dissected, highlighting their indispensable functions in resource management and user interface interaction. Das elucidates how the kernel acts as the central nervous system, orchestrating process scheduling, memory allocation, and device management. Meanwhile, the shell serves as the gateway for user commands, bridging the gap between human input and machine execution. 💻
The narrative then shifts to a captivating exploration of prominent desktop OSs, Windows, macOS, and Linux. Windows, with its globally ubiquitous presence and user-friendly interface, emerges as a cornerstone in personal computing history. macOS, lauded for its sleek design and seamless integration with Apple's ecosystem, stands as a beacon of stability and creativity. Linux, an open-source marvel, offers unparalleled flexibility and security, revolutionizing the computing landscape. 🖥️
Moving to the realm of mobile devices, Das unravels the dominance of Android and iOS. Android's open-source ethos fosters a vibrant ecosystem of customization and innovation, while iOS boasts a seamless user experience and robust security infrastructure. Meanwhile, discontinued platforms like Symbian and Palm OS evoke nostalgia for their pioneering roles in the smartphone revolution.
The journey concludes with a reflection on the ever-evolving landscape of OS, underscored by the emergence of real-time operating systems (RTOS) and the persistent quest for innovation and efficiency. As technology continues to shape our world, understanding the foundations and evolution of operating systems remains paramount. Join Pravash Chandra Das on this illuminating journey through the heart of computing. 🌟
leewayhertz.com-AI in predictive maintenance Use cases technologies benefits ...
Predictive maintenance is a proactive approach that anticipates equipment failures before they happen. At the forefront of this innovative strategy is Artificial Intelligence (AI), which brings unprecedented precision and efficiency. AI in predictive maintenance is transforming industries by reducing downtime, minimizing costs, and enhancing productivity.
System Design Case Study: Building a Scalable E-Commerce Platform - Hiike
This case study explores designing a scalable e-commerce platform, covering key requirements, system components, and best practices.
Columbus Data & Analytics Wednesdays - June 2024
Columbus Data & Analytics Wednesdays, June 2024 with Maria Copot 20
Fueling AI with Great Data with Airbyte Webinar
This talk will focus on how to collect data from a variety of sources, leveraging this data for RAG and other GenAI use cases, and finally charting your course to productionalization.
Unlock the Future of Search with MongoDB Atlas_ Vector Search Unleashed.pdf
Discover how MongoDB Atlas and vector search technology can revolutionize your application's search capabilities. This comprehensive presentation covers:
* What is Vector Search?
* Importance and benefits of vector search
* Practical use cases across various industries
* Step-by-step implementation guide
* Live demos with code snippets
* Enhancing LLM capabilities with vector search
* Best practices and optimization strategies
Perfect for developers, AI enthusiasts, and tech leaders. Learn how to leverage MongoDB Atlas to deliver highly relevant, context-aware search results, transforming your data retrieval process. Stay ahead in tech innovation and maximize the potential of your applications.
#MongoDB #VectorSearch #AI #SemanticSearch #TechInnovation #DataScience #LLM #MachineLearning #SearchTechnology
Building Production Ready Search Pipelines with Spark and Milvus
Spark is the widely used ETL tool for processing, indexing and ingesting data to serving stack for search. Milvus is the production-ready open-source vector database. In this talk we will show how to use Spark to process unstructured data to extract vector representations, and push the vectors to Milvus vector database for search serving.
A Comprehensive Guide to DeFi Development Services in 2024
DeFi represents a paradigm shift in the financial industry. Instead of relying on traditional, centralized institutions like banks, DeFi leverages blockchain technology to create a decentralized network of financial services. This means that financial transactions can occur directly between parties, without intermediaries, using smart contracts on platforms like Ethereum.
In 2024, we are witnessing an explosion of new DeFi projects and protocols, each pushing the boundaries of what’s possible in finance.
In summary, DeFi in 2024 is not just a trend; it’s a revolution that democratizes finance, enhances security and transparency, and fosters continuous innovation. As we proceed through this presentation, we'll explore the various components and services of DeFi in detail, shedding light on how they are transforming the financial landscape.
At Intelisync, we specialize in providing comprehensive DeFi development services tailored to meet the unique needs of our clients. From smart contract development to dApp creation and security audits, we ensure that your DeFi project is built with innovation, security, and scalability in mind. Trust Intelisync to guide you through the intricate landscape of decentralized finance and unlock the full potential of blockchain technology.
Ready to take your DeFi project to the next level? Partner with Intelisync for expert DeFi development services today!
June Patch Tuesday
Ivanti’s Patch Tuesday breakdown goes beyond patching your applications and brings you the intelligence and guidance needed to prioritize where to focus your attention first. Catch early analysis on our Ivanti blog, then join industry expert Chris Goettl for the Patch Tuesday Webinar Event. There we’ll do a deep dive into each of the bulletins and give guidance on the risks associated with the newly-identified vulnerabilities.
Azure API Management to expose backend services securely
How to use Azure API Management to expose backend service securely
Recently uploaded (20)
Skybuffer AI: Advanced Conversational and Generative AI Solution on SAP Busin...
Skybuffer AI: Advanced Conversational and Generative AI Solution on SAP Busin...
Deep Dive: Getting Funded with Jason Jason Lemkin Founder & CEO @ SaaStr
Deep Dive: Getting Funded with Jason Jason Lemkin Founder & CEO @ SaaStr
Presentation of the OECD Artificial Intelligence Review of Germany
Presentation of the OECD Artificial Intelligence Review of Germany
Best 20 SEO Techniques To Improve Website Visibility In SERP
Best 20 SEO Techniques To Improve Website Visibility In SERP
Operating System Used by Users in day-to-day life.pptx
Operating System Used by Users in day-to-day life.pptx
leewayhertz.com-AI in predictive maintenance Use cases technologies benefits ...
leewayhertz.com-AI in predictive maintenance Use cases technologies benefits ...
System Design Case Study: Building a Scalable E-Commerce Platform - Hiike
System Design Case Study: Building a Scalable E-Commerce Platform - Hiike
WeTestAthens: Postman's AI & Automation Techniques
WeTestAthens: Postman's AI & Automation Techniques
Unlock the Future of Search with MongoDB Atlas_ Vector Search Unleashed.pdf
Unlock the Future of Search with MongoDB Atlas_ Vector Search Unleashed.pdf
Building Production Ready Search Pipelines with Spark and Milvus
Building Production Ready Search Pipelines with Spark and Milvus
A Comprehensive Guide to DeFi Development Services in 2024
A Comprehensive Guide to DeFi Development Services in 2024
Azure API Management to expose backend services securely
Azure API Management to expose backend services securely
Marketing of Protein and Peptide Pharmaceuticals
- 1. Marketing of Peptide, Proteins, Author: Sasan Nasoohi Function : Sales Manager Schering Plough Date : Nov 08 Presented to Ph.D. students of Faculty of Pharmacy of Tehran University
- 5. From cells to patients
- 15. What is PharmacoEconomics (PE)? Inputs Costs Health Care Outcomes
- 22. The top 10 biotechnology companies
- 34. We sell benefits